← Back to Search

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Baltimore, MD
N/A
Recruiting
Led By Jeff Bethony
Research Sponsored by AIDS Malignancy Consortium
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, anticipated to be 10 years
Awards & highlights
No Placebo-Only Group

Summary

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.

See full description
Eligible Conditions
  • Plasmablastic Lymphoma
  • Cancer
  • Kaposi's Sarcoma
  • Kaposi Sarcoma
  • Anal Cancer
  • Blood Cancers
  • HIV/AIDS
  • Lymphoma
  • Castleman's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, anticipated to be 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, anticipated to be 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of biospecimens collected

Side effects data

From 2024 Phase 3 trial • 218 Patients • NCT00557193
70%
Alanine aminotransferase increased
58%
Mucositis oral
57%
Aspartate aminotransferase increased
57%
Febrile neutropenia
53%
Infections and infestations - Other, specify
48%
Neutrophil count decreased
33%
Hypokalemia
25%
Diarrhea
23%
White blood cell decreased
22%
Catheter related infection
22%
Anorexia
15%
Fever
15%
Platelet count decreased
13%
Dehydration
12%
Upper respiratory infection
12%
Skin infection
12%
Urinary tract infection
8%
Lung infection
8%
Skin ulceration
8%
Hypocalcemia
8%
Hyponatremia
7%
Alkaline phosphatase increased
7%
Anemia
7%
Weight loss
7%
Hyperglycemia
7%
Hypoglycemia
7%
Hypoxia
5%
Bronchial infection
5%
Enterocolitis infectious
5%
GGT increased
5%
Hypoalbuminemia
5%
Soft tissue infection
5%
Lymphocyte count decreased
5%
Skin and subcutaneous tissue disorders - Other, specify
3%
Sepsis
3%
Vomiting
3%
Pain
3%
Hypophosphatemia
3%
Pain of skin
3%
Oral pain
3%
Anaphylaxis
3%
Penile infection
3%
Erythema multiforme
2%
Wound infection
2%
Esophagitis
2%
Blood and lymphatic system disorders - Other, specify
2%
Generalized muscle weakness
2%
Cardiac disorders - Other, specify
2%
Sinus tachycardia
2%
Irritability
2%
Scrotal infection
2%
Small intestine infection
2%
Fracture
2%
Wound complication
2%
Hyperkalemia
2%
Hypertriglyceridemia
2%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
2%
Penile pain
2%
Pharyngeal mucositis
2%
Pleural effusion
2%
Stridor
2%
Dry skin
2%
Surgical and medical procedures - Other, specify
2%
Hypotension
2%
Acute kidney injury
2%
Anal mucositis
2%
Gastritis
2%
Nausea
2%
Bladder infection
2%
Investigations - Other, specify
2%
Peripheral motor neuropathy
2%
Peripheral sensory neuropathy
2%
Epistaxis
2%
Pneumonitis
2%
Pulmonary edema
2%
Respiratory failure
2%
Hypertension
2%
Enterocolitis
2%
Acidosis
2%
Renal and urinary disorders - Other, specify
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A (Standard Risk MLL-G)
Arm B (IR/HR MLL-R Chemotherapy)
Arm C (Efficacy/ Dose Level 2)
Induction (All Patients)
Post Induction (Follow-up Only)
Arm C (Safety/ Dose Level 1)
Arm C (Safety/ Dose Level 2)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Observational (biospecimen collection)Experimental Treatment1 Intervention
Patients undergo collection of fresh blood and/or tumor tissue samples
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~1810

Find a Location

Closest Location:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Who is running the clinical trial?

AIDS Malignancy ConsortiumLead Sponsor
63 Previous Clinical Trials
9,384 Total Patients Enrolled
3 Trials studying Plasmablastic Lymphoma
33 Patients Enrolled for Plasmablastic Lymphoma
National Cancer Institute (NCI)NIH
14,071 Previous Clinical Trials
41,180,631 Total Patients Enrolled
108 Trials studying Plasmablastic Lymphoma
6,883 Patients Enrolled for Plasmablastic Lymphoma
Jeff BethonyPrincipal InvestigatorAIDS Malignancy Consortium
~133 spots leftby Aug 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top